The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

As recently as five years ago, China was a bit player in biotechnology as their percentage of worldwide clinical trial activity was in the single digits. Over the last five years, China’s share of the ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Aragen, based in Hyderabad, says it will use the funds to boost manufacturing capacity for newer treatment modalities, such ...

Pharma Sector Multibagger Opportunity - Explore how India could win big in the CDMO space with China-Plus-One strategy, ...

The Indian pharmaceutical market sees negative volume growth in Q3FY25 but benefits from strong pricing and new product ...